Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | NNMT | P40261 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31141991 | 1.00 | POLB (0.73) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL29859234 | 0.85 | TDP1 (1.00) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL198490 | 0.85 | TDP1 (1.00) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL3864064 | 0.83 | POLB (0.71) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL11605385 | 0.83 | TDP1 (0.71) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL5010608 | 0.83 | POLB (0.71) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL2414594 | 0.83 | POLB (0.51) | POLBTDP1RAB9ANPC1HPGD | |
| Hydrochloric Acid SCHEMBL10988320 | 0.83 | TDP1 (0.96) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL14946913 | 0.81 | POLB (0.63) | POLBTDP1RAB9ANPC1HPGD | |
| SCHEMBL14946915 | 0.81 | POLB (0.63) | POLBTDP1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013006000-A2 | METHOD FOR DETECTING BREAST CANCER USING RESPIRATORY GAS | 주식회사 알앤엘내츄럴 (KR) | 2013-01-10 | — | — | WO | claimed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2970183-A2 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | Musc Foundation for Research Development (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2014160143-A2 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-2138492-A1 | Substituted pyrimidin-4-one derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156865-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | CLN6, AREG, HASPIN | POLB 870/4885TDP1 681/4885RAB9A 1290/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | POLB 3037/4885TDP1 2324/4885RAB9A 2185/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | POLB 2041/4885TDP1 3315/4885RAB9A 1490/4885 |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | CLN6, AREG, HASPIN | POLB 870/4885TDP1 681/4885RAB9A 1290/4885 |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | POLB 3885/4885TDP1 3167/4885RAB9A 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.